TScan Therapeutics, Inc. (TCRX) stock
Close on Nov 11, 2026Market cap $12.58MP/E –Yield –
TScan Therapeutics, Inc. saw revenue fall 38.4% to $5.19M over the twelve months to Sep 30, 2026. Free cash flow was -$111.67M. At the latest close the market valued the company at $12.58M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $12.58M
- P/E ratio
- –
- Price to sales
- 1.77
- Price to book
- 0.18
- Dividend yield
- –
- Free cash flow yield
- -941.50%
Fundamentals
- Revenue
- $5.19M
- Net income
- -$115.09M
- EPS, diluted
- -$0.88
- Free cash flow
- -$111.67M
- Book value per share
- $0.29
- Diluted shares
- 130M
Trading
- Next earnings
- Nov 11, 2026 (estimated, before the open)
- Previous close
- $0.19
- Open
- $0.19
- Day's range
- $0.18 – $0.19
- Volume
- 292,700
- Average volume (20 days)
- 486,578
- Beta (5 years)
- 0.94
- 52-week range
- $0.17 – $1.47
- RSI (14 days)
- 36.1
- Volatility (1 year)
- 93.9%
- Relative volume
- 0.40×
- WACC
- 7.5%
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | TCRX | S&P 500 | Difference | TCRX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -22.0% | -2.4% | −19.6 pts | ||
| 3 months | -76.1% | -1.2% | −75.0 pts | ||
| Year to date | -81.4% | +12.3% | −93.7 pts | ||
| 1 year | -84.8% | +12.4% | −97.2 pts | ||
| 3 years | -95.9% | +78.8% | −174.7 pts | -65.4% | +21.4% |
| 5 years | -97.9% | +75.2% | −173.0 pts | -53.7% | +11.9% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases TScan Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Results
- Update
- Update
- Results
About TScan Therapeutics
Biological Products, (No Diagnostic Substances)
The company is a clinical-stage biotechnology firm that develops T cell receptor-engineered T cell therapies to treat cancer and autoimmune conditions. Its primary clinical focus is on hematologic malignancies, led by candidate TSC-101 for patients with acute myeloid leukemia and myelodysplastic syndrome receiving allogeneic hematopoietic cell transplantation. The company is also developing candidates TSC-102-A01 and TSC-102-A03 targeting CD45, as well as preclinical in vivo multiplex therapies for solid tumors. In autoimmune indications, it discovers targets for conditions such as ankylosing spondylitis, ulcerative colitis, and Crohn's disease. Its potential end customers are patients suffering from these cancers and immune-mediated disorders.
Company profile, executives and historyTScan Therapeutics stock: common questions
What is TScan Therapeutics's stock price?
TCRX closed at $0.19 on Nov 11, 2026, up 0.22% on the day. Over the past 52 weeks it traded between $0.17 and $1.47.
What is TScan Therapeutics's market cap?
TScan Therapeutics was worth $12.58M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is TCRX's P/E ratio?
TScan Therapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.88), so it has no meaningful P/E ratio.
How much revenue does TScan Therapeutics make?
TScan Therapeutics reported revenue of $5.19M for the twelve months to Sep 30, 2026, down 38.4% from a year earlier.
Does TScan Therapeutics pay a dividend?
No. TScan Therapeutics has not paid a cash dividend over the last twelve months.
When does TScan Therapeutics report earnings next?
TScan Therapeutics is expected to report Q3 FY2026 results on Nov 11, 2026, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has TCRX stock performed over the past year?
Including dividends, TCRX returned -84.8% over the past year, against +12.4% for the S&P 500.
How many TCRX shares are sold short?
2M shares were sold short at the latest FINRA report, 4.43% of the float, or 4.7 days of average trading volume.
Who are TScan Therapeutics's competitors?
Companies most similar to TScan Therapeutics by business, industry and size include FATE, ATRA, CRBU, IPHA, MRKR.
See a number that looks wrong?